Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZenecas Byetta in 2005
There is no benefit in holding one dose of these medications and there is potential harm
11 Every meal and snack should be viewed as an opportunity to provide the body with the essential building blocks it needs to function optimally, support fat loss, and preserve vital muscle tissue
Retrospective Study In a retrospective study of more than 83,000 obese individuals, semaglutide was associated with a more than 50% lower incidence of alcohol use disorder (AUD) over a period of 12 months, regardless of age, gender, race, or diabetes status
In addition to the possible health risks associated with the use of GLP-1 drugs, these therapies are associated with a high out-of-pocket cost for individuals who do not qualify for their use through insurance, such as those wanting to lose weight without falling into the obesity or diabetes categories
J Neurosci 2006, 26: 696707